LEAP THERAPEUTICS INC (LPTX) Stock Price, Forecast & Analysis
USA - NASDAQ:LPTX - US52187K2006 - Common Stock
LPTX Key Statistics, Chart & Performance
The current stock price of LPTX is 2.05 USD. In the past month the price increased by 228.53%. In the past year, price decreased by -25.18%.
LPTX Latest News, Press Relases and Analysis
LPTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.81 | 414.26B | ||
| AMGN | AMGEN INC | 15.73 | 185.16B | ||
| GILD | GILEAD SCIENCES INC | 15.42 | 156.66B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.1 | 111.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 76.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 917.17 | 61.31B | ||
| INSM | INSMED INC | N/A | 42.88B | ||
| NTRA | NATERA INC | N/A | 29.53B | ||
| BIIB | BIOGEN INC | 10.08 | 24.74B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.11 | 21.61B | ||
| INCY | INCYTE CORP | 16.23 | 20.35B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.29 | 13.80B |
Related stock screener links
About LPTX
Company Profile
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The firm is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The firm also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Company Info
LEAP THERAPEUTICS INC
47 Thorndike St, Suite B1-1
Cambridge MASSACHUSETTS 02141 US
CEO: Douglas E. Onsi
Employees: 52
Phone: 16177140360
LEAP THERAPEUTICS INC / LPTX FAQ
What does LPTX do?
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The firm is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The firm also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
What is the current price of LPTX stock?
The current stock price of LPTX is 2.05 USD. The price increased by 368.57% in the last trading session.
Does LPTX stock pay dividends?
LPTX does not pay a dividend.
How is the ChartMill rating for LEAP THERAPEUTICS INC?
LPTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is LEAP THERAPEUTICS INC worth?
LEAP THERAPEUTICS INC (LPTX) has a market capitalization of 116.13M USD. This makes LPTX a Micro Cap stock.
LPTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LPTX. When comparing the yearly performance of all stocks, LPTX is one of the better performing stocks in the market, outperforming 99.48% of all stocks.
LPTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LPTX. LPTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LPTX Financial Highlights
Over the last trailing twelve months LPTX reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS increased by 36.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -327.74% | ||
| ROE | -1148.94% | ||
| Debt/Equity | 0 |